Nomura: Maintains a "buy" rating on SINOPHARM (01099) and lowers the target price to 25.09 Hong Kong dollars.

27/02/2025

According to the estimate, the revenue of the company in the last quarter is expected to decrease by 0.4% year-on-year, while the profit is expected to drop by 2.8%.

Nomura released a research report stating that they maintain a "buy" rating for SINOPHARM (01099) with a target price lowered from 28.46 Hong Kong dollars to 25.09 Hong Kong dollars. The bank has lowered the group's sales forecast for 2024 and 2025 by 1.4% each, and reduced profit forecasts by 5.3% each to reflect profit pressure and credit losses or impairments. The bank estimates that Sinopharm's revenue in the last quarter will decrease by 0.4% year-on-year, while profits will drop by 2.8%.